CA3250834A1 - SOLID, DELAYED-RELEASE COMPOSITION COMPRISING BRADYKININ B2 RECEPTOR ANTAGONISTS - Google Patents

SOLID, DELAYED-RELEASE COMPOSITION COMPRISING BRADYKININ B2 RECEPTOR ANTAGONISTS

Info

Publication number
CA3250834A1
CA3250834A1 CA3250834A CA3250834A CA3250834A1 CA 3250834 A1 CA3250834 A1 CA 3250834A1 CA 3250834 A CA3250834 A CA 3250834A CA 3250834 A CA3250834 A CA 3250834A CA 3250834 A1 CA3250834 A1 CA 3250834A1
Authority
CA
Canada
Prior art keywords
bradykinin
receptor antagonists
release composition
solid extended
extended
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3250834A
Other languages
English (en)
French (fr)
Inventor
Christoph Gibson
Original Assignee
Pharvaris GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharvaris GmbH filed Critical Pharvaris GmbH
Publication of CA3250834A1 publication Critical patent/CA3250834A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3250834A 2022-03-25 2023-03-27 SOLID, DELAYED-RELEASE COMPOSITION COMPRISING BRADYKININ B2 RECEPTOR ANTAGONISTS Pending CA3250834A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22164471.9 2022-03-25
EP22164471 2022-03-25
PCT/EP2023/057792 WO2023180576A1 (en) 2022-03-25 2023-03-27 Solid extended-release composition comprising bradykinin b2-receptor antagonists

Publications (1)

Publication Number Publication Date
CA3250834A1 true CA3250834A1 (en) 2023-09-28

Family

ID=80952430

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3250834A Pending CA3250834A1 (en) 2022-03-25 2023-03-27 SOLID, DELAYED-RELEASE COMPOSITION COMPRISING BRADYKININ B2 RECEPTOR ANTAGONISTS

Country Status (24)

Country Link
US (1) US20250228782A1 (enExample)
EP (2) EP4499039B1 (enExample)
JP (1) JP2025510860A (enExample)
KR (1) KR20240161195A (enExample)
CN (1) CN119136786A (enExample)
AU (1) AU2023240388A1 (enExample)
CA (1) CA3250834A1 (enExample)
CO (1) CO2024012885A2 (enExample)
DK (1) DK4499039T3 (enExample)
ES (1) ES3062435T3 (enExample)
FI (1) FI4499039T3 (enExample)
HR (1) HRP20260203T1 (enExample)
IL (1) IL315700A (enExample)
LT (1) LT4499039T (enExample)
MA (1) MA69210B1 (enExample)
MX (1) MX2024011704A (enExample)
PL (1) PL4499039T3 (enExample)
PT (1) PT4499039T (enExample)
RS (1) RS67776B1 (enExample)
SI (1) SI4499039T1 (enExample)
SM (1) SMT202600057T1 (enExample)
TW (1) TW202345810A (enExample)
WO (1) WO2023180576A1 (enExample)
ZA (1) ZA202408059B (enExample)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1168667A (zh) 1994-10-27 1997-12-24 藤沢药品工业株式会社 用作缓激肽拮抗剂的吡啶并嘧啶酮，喹啉和稠合的n-杂环化合物
FR2737892B1 (fr) 1995-08-17 1997-10-24 Fournier Ind & Sante Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique
GB9602029D0 (en) 1996-02-01 1996-04-03 Fujisawa Pharmaceutical Co New heterocyclic compounds
DE19609827A1 (de) 1996-03-13 1997-09-18 Hoechst Ag Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten
DE19610784A1 (de) 1996-03-19 1997-09-25 Hoechst Ag Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
AUPN952696A0 (en) 1996-04-29 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
DE19712960A1 (de) 1997-03-27 1998-10-01 Hoechst Ag Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten
EP1085895A1 (en) 1998-06-08 2001-03-28 Advanced Medicine, Inc. Bradykinin antagonists
EP1123288A1 (en) 1998-10-21 2001-08-16 Fujisawa Pharmaceutical Co., Ltd. Vitreous form of known bradykinin antagonist
FR2790260B1 (fr) 1999-02-26 2001-05-04 Fournier Ind & Sante Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique
CA2364178C (en) 2000-12-05 2006-01-10 Yasuhiro Katsu N-benzenesulfonyl l-proline compounds as bradykinin antagonists
JP2005525398A (ja) 2002-04-10 2005-08-25 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ブラジキニン受容体モジュレーターとして有用な新規なヘテロアリールアルキルアミド誘導体
ITMI20021247A1 (it) 2002-06-07 2003-12-09 Menarini Ricerche Spa Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
ITMI20041963A1 (it) 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽ｂ２受體調節劑
AR073304A1 (es) 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
KR20150127718A (ko) 2013-03-14 2015-11-17 샤이어 휴먼 지네틱 테라피즈 인크. Ｂ2-브라디키닌 수용체 매개 혈관부종의 치료 방법
SMT202200154T1 (it) * 2017-11-24 2022-05-12 Pharvaris Netherlands B V Nuovi antagonisti del recettore della bradichinina b2
AR118983A1 (es) * 2019-05-23 2021-11-17 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
CA3198246A1 (en) * 2020-11-12 2022-05-19 Pharvaris Gmbh Prophylaxis and treatment of angioedema

Also Published As

Publication number Publication date
US20250228782A1 (en) 2025-07-17
SI4499039T1 (sl) 2026-04-30
IL315700A (en) 2024-11-01
LT4499039T (lt) 2026-02-25
ES3062435T3 (en) 2026-04-10
AU2023240388A1 (en) 2024-11-07
PT4499039T (pt) 2026-02-17
MA69210B1 (fr) 2026-02-27
CO2024012885A2 (es) 2024-10-10
PL4499039T3 (pl) 2026-03-30
TW202345810A (zh) 2023-12-01
FI4499039T3 (fi) 2026-02-05
MX2024011704A (es) 2024-11-08
JP2025510860A (ja) 2025-04-15
EP4499039B1 (en) 2025-12-03
CN119136786A (zh) 2024-12-13
ZA202408059B (en) 2026-01-28
SMT202600057T1 (it) 2026-03-09
HRP20260203T1 (hr) 2026-03-27
EP4499039A1 (en) 2025-02-05
DK4499039T3 (da) 2026-02-16
EP4684830A2 (en) 2026-01-28
KR20240161195A (ko) 2024-11-12
WO2023180576A1 (en) 2023-09-28
EP4684830A3 (en) 2026-04-01
RS67776B1 (sr) 2026-03-31

Similar Documents

Publication Publication Date Title
AU2022208128A9 (en) Sustained-release preparation composition
EP4279065A4 (en) DELAYED-RELEASE PREPARATION COMPOSITION
HK40123496A (zh) 包含缓激肽b2受体拮抗剂的固体缓释组合物
CA3250835A1 (en) SOLID COMPOSITION COMPRISING SOLUBILIZED BRADYKININ B2 RECEPTOR ANTAGONISTS
EP4137502A4 (en) VIPR2 ANTAGONIST PEPTIDE
RS67776B1 (sr) Čvrsta kompozicija sa produženim oslobađanjem koja sadrži bradikininske antagoniste b2 receptora
CA3256301A1 (en) COMPOSITIONS
HK40121803A (en) Solid composition comprising solubilised bradykinin b2-receptor antagonists
EP4093716A4 (en) PHOSPHATE CEMENT COMPOSITIONS
CA3297759A1 (en) Bacteriophage compositions
CA3277886A1 (en) Parp1 inhibitors
AU2024371546A1 (en) Cement compositions
CA3264627A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS OF ADAGRASIB
AU2024392540A1 (en) Senolytic compositions
CA3301712A1 (en) Hemostatic powder
HK40122551A (en) Compositions comprising aticaprant
CA3304170A1 (en) Pharmaceutical compositions
CA3293008A1 (en) Pharmaceutical compositions
CA3274331A1 (en) Milvexian pharmaceutical compositions
HK40130274A (zh) 米尔维仙药物组合物
AU2024217663A1 (en) Milvexian pharmaceutical compositions
CA3304614A1 (en) Compositions
CA3304437A1 (en) Aquafeed compositions
CA3296889A1 (en) Biocatalytical compositions
AU2023903471A0 (en) Cement compositions

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240920

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250213

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250213

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250213

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250214

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250220

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250318

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250318

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250318

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250423

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250423

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20250423

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250512

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260313

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260313

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260515

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260515

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20260515

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260602